All In MedTech

FDA Clearance Tracker · P010050

IMMULITE 2000 XPI HBSAG

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Jul 26, 2002 (this decision)Source: openFDAMethods & limitations

PMA

The decision

FDA number
P010050
Device name
IMMULITE 2000 XPI HBSAG
Applicant location
Llanberis
Received
Aug 31, 2001
Decided
Jul 26, 2002
Decision
Approved (reclassified)
Supplements
20 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class II
Regulation
21 CFR 866.3172

Every decision under product code LOM

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE IMMULITE HBSAG, IMMULITE 2000 HBSAG AND IMMULITE HBSAG CONFIRMATORY KIT. THESE DEVICES ARE INDICATED FOR: IMMULITE HBSAG: IMMULITE HBSAG IS A SOLID-PHASED CHEMILUMINESCENT ENZYME IMMUNOASSAY DESIGNED FOR IN VITRO USE WITH THE IMMULITE AUTOMATED IMMUNOASSAY ANALYZER FOR THE QUALITATIVE DETECTION OF HEPATITIS B SURFACE ANTIGEN (HBSAG) IN HUMAN SERUM OR PLASMA (EDTA, HEPARINIZED, CITRATE). IT IS INTENDED FOR IN VITRO DIAGNOSTIC USE FOR THE LABORATORY DIAGNOSIS OF ACUTE AND CHRONIC HEPATITIS B VIRUS INFECTIONS IN CONJUNCTION WITH OTHER SEROLOGICAL AND CLINICAL INFORMATION. IN ADDITION, THIS ASSAY MAY BE USED TO SCREEN FOR HEPATITIS B INFECTION IN PREGNANT WOMEN TO IDENTIFY NEONATES WHO ARE AT HIGH RISK OF ACQUIRING HBV DURING THE PERINATAL PERIOD. IMMULITE. 2000 HBSAG: IMMULITE 2000 HBSAG IS A SOLID-PHASE CHEMILUMINESCENT ENZYME IMMUNOASSAY DESIGNED FOR IN VITRO USE WITH THE IMMULITE 2000 AUTOMATED IMMUNOASSAY ANALYZER FOR THE QUALITATIVE DETECTION OF HEPATITIS B SURFACE ANTIGEN (HBSAG) IN HUMAN SERUM OR PLASMA (EDTA, HEPARINIZED, CITRATE). IT IS INTENDED FOR IN VITRO DIAGNOSTIC USE FOR THE LABORATORY DIAGNOSIS OF ACUTE AND CHRONIC HEPATITIS B VIRUS INFECTIONS IN CONJUNCTION WITH OTHER SEROLOGICAL AND CLINICAL INFORMATION. IN ADDITION, THIS ASSAY MAY BE USED TO SCREEN FOR HEPATITIS B INFECTION IN PREGNANT WOMEN TO IDENTIFY NEONATES WHO ARE AT HIGH RISK OF ACQUIRING HBV DURING THE PERINATAL PERIOD. IMMULITE HBSAG CONFIRMATORY KIT: IMMULITE HBSAG CONFIRMATORY IS INTENDED FOR IN VITRO DIAGNOSTIC USE IN CONJUNCTION WITH THE IMMULITE HBSAG OR THE IMMULITE 2000 HBSAG ASSAYS FOR THE CONFIRMATION OF THE PRESENCE OF HEPATITIS B SURFACE ANTIGEN (HBSAG) IN HUMAN SERUM OR PLASMA (EDTA, HEPARINIZED, CITRATE) THAT WERE REPEATEDLY POSITIVE WHEN TESTED BY IMMULITE OR IMMULITE 2000 HBSAG.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LOM. The earliest in FDA's data is P780016-S002, decided Mar 17, 1980.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Siemens Healthcare Diagnostics Products, Ltd.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.